CN113631168B - Gpr35调节剂 - Google Patents

Gpr35调节剂 Download PDF

Info

Publication number
CN113631168B
CN113631168B CN202080024043.7A CN202080024043A CN113631168B CN 113631168 B CN113631168 B CN 113631168B CN 202080024043 A CN202080024043 A CN 202080024043A CN 113631168 B CN113631168 B CN 113631168B
Authority
CN
China
Prior art keywords
alkyl
branched
straight
pharmaceutically acceptable
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080024043.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113631168A (zh
Inventor
罗伯特·希古奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometheus Biosciences Inc
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of CN113631168A publication Critical patent/CN113631168A/zh
Application granted granted Critical
Publication of CN113631168B publication Critical patent/CN113631168B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080024043.7A 2019-01-24 2020-01-23 Gpr35调节剂 Active CN113631168B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (2)

Publication Number Publication Date
CN113631168A CN113631168A (zh) 2021-11-09
CN113631168B true CN113631168B (zh) 2024-11-19

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024043.7A Active CN113631168B (zh) 2019-01-24 2020-01-23 Gpr35调节剂

Country Status (13)

Country Link
US (2) US11053251B2 (https=)
EP (1) EP3914256B1 (https=)
JP (1) JP7588077B2 (https=)
KR (1) KR102863894B1 (https=)
CN (1) CN113631168B (https=)
AU (1) AU2020210930B2 (https=)
BR (1) BR112021014566A2 (https=)
CA (1) CA3127786A1 (https=)
IL (1) IL285074B2 (https=)
MA (1) MA54825A (https=)
MX (1) MX2021008941A (https=)
TW (1) TWI845600B (https=)
WO (1) WO2020154492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
EP4185379A4 (en) * 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987160A (en) * 1970-12-15 1976-10-19 May & Baker Limited Pharmaceutical compositions comprising azapurinones useful in treating allergic respiratory disorders
WO2004035584A1 (fr) * 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
KR102481020B1 (ko) 2014-06-29 2022-12-26 프로파일 프러덕츠 엘엘씨 나무껍질 및 목재 섬유 성장 배지
WO2018195328A1 (en) * 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3920953A4 (en) 2019-02-08 2022-12-14 Cedars-Sinai Medical Center METHODS, SYSTEMS AND KITS FOR THE TREATMENT OF INFLAMMATORY DISEASES TARGETED FOR IL18R1
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
EP4185379A4 (en) 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987160A (en) * 1970-12-15 1976-10-19 May & Baker Limited Pharmaceutical compositions comprising azapurinones useful in treating allergic respiratory disorders
WO2004035584A1 (fr) * 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antiallergic Activity of 2-Phenyl-8-azapurin-6-ones;B. J. Broughton et al.;《Journal of Medicinal Chemistry》;第18卷(第11期);第1117-1122页 *
GPR35 as a novel therapeutic target;A. E. MacKenzie et al.;《Frontier in endocrinology》;第2卷;第1-10页 *

Also Published As

Publication number Publication date
US20210380590A1 (en) 2021-12-09
CA3127786A1 (en) 2020-07-30
CN113631168A (zh) 2021-11-09
MX2021008941A (es) 2021-10-13
EP3914256B1 (en) 2024-05-29
WO2020154492A1 (en) 2020-07-30
US20200239476A1 (en) 2020-07-30
KR20210119485A (ko) 2021-10-05
US11773101B2 (en) 2023-10-03
IL285074A (en) 2021-09-30
MA54825A (fr) 2021-12-01
IL285074B1 (en) 2024-08-01
EP3914256A4 (en) 2022-09-28
AU2020210930B2 (en) 2025-08-14
JP7588077B2 (ja) 2024-11-21
EP3914256A1 (en) 2021-12-01
IL285074B2 (en) 2024-12-01
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
JP2022518523A (ja) 2022-03-15
AU2020210930A1 (en) 2021-09-09
US11053251B2 (en) 2021-07-06
KR102863894B1 (ko) 2025-09-23

Similar Documents

Publication Publication Date Title
CN113631168B (zh) Gpr35调节剂
CA2903293C (en) Heterocyclic compounds and uses thereof
JP5806417B2 (ja) Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン
IL307559A (en) Deuterated dihydroorotate dihydrogenase (DHODH) inhibitors
JP2025532670A (ja) Ｐｃｓｋ９阻害剤及びその使用方法
TW202332436A (zh) 治療用化合物
NZ729494A (en) Pyrazolothiazole compound and medicine comprising same
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ
US20230151017A1 (en) Therapeutic agents targeting gpr35
JP7680371B2 (ja) Ａｂｈｄ１２阻害剤並びにその作製及び使用方法
HK40059523A (en) Gpr35 modulators
CN121226261A (zh) 作为wrn抑制剂的含芳香环化合物及其应用
TWI910148B (zh) 芳基或雜芳基衍生物
WO2026041127A1 (zh) Nlrp3抑制剂及其制备方法和用途
EA048936B1 (ru) Модуляторы gpr35
HK40105573A (zh) Lpa受体拮抗剂及其用途
IL324265A (en) Cndp2 modulators and methods for their use
CN113015736A (zh) 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059523

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant